Azilect contains rasagiline, which slows dopamine breakdown in brain pathways affected by Parkinson’s disease. It is prescribed for adults with Parkinson’s disease to help manage movement symptoms…
Azilect contains rasagiline, which slows dopamine breakdown in brain pathways affected by Parkinson’s disease. It is prescribed for adults with Parkinson’s disease to help manage movement symptoms such as slowness, stiffness and tremor. Its role may include reducing daily “off-time” when mobility becomes less controlled.
Azilect contains rasagiline, which slows dopamine breakdown in brain pathways affected by Parkinson’s disease. Rasagiline belongs to the monoamine oxidase B inhibitor class, within the wider group of monoamine oxidase inhibitors (MAOIs).
It may be prescribed for adults with Parkinson’s disease as treatment on its own or alongside levodopa, depending on symptoms and the treatment plan.
Azilect may help control motor symptoms, but the response differs between individuals.
Rasagiline can be used as monotherapy in some earlier treatment plans or as an adjunct to levodopa when motor control fluctuates.
Azilect is the product name for tablets containing rasagiline, supplied as rasagiline mesylate. Rasagiline belongs to the monoamine oxidase B inhibitor class, within the wider group of monoamine oxidase inhibitors (MAOIs). It may be prescribed for adults with Parkinson’s disease as treatment on its own or alongside levodopa, depending on symptoms and the treatment plan.
The U.S. Food and Drug Administration (FDA) approved rasagiline for Parkinson’s disease, and the medicine is also covered by European regulatory product information. Its purpose is symptom control. It does not reverse the underlying loss of dopamine-producing nerve cells.
Monoamine oxidase B, or MAO-B, is an enzyme involved in dopamine breakdown. By inhibiting this enzyme, rasagiline allows dopamine to remain available for longer in relevant brain pathways.
The selective MAO-B action does not remove the need for interaction screening. Other MAOIs, some antidepressants, certain pain medicines and several non-prescription products can create clinically important risks when combined with rasagiline.
Parkinson’s disease can cause bradykinesia, rigidity, resting tremor and changes in walking or balance. Bradykinesia means unusually slow movement; rigidity refers to muscle stiffness that makes movement feel restricted.
Azilect may help control motor symptoms, but the response differs between individuals. Disease stage, existing medicines, cognition, blood pressure, sleep patterns and other health conditions all affect treatment decisions.
Rasagiline is a monoamine oxidase B inhibitor. It reduces enzymatic dopamine breakdown, leaving more dopamine available for signalling in movement-related areas of the brain.
Dopamine does not simply act as an “energy chemical”. In Parkinson’s disease, reduced dopamine signalling affects the smooth initiation and control of movement. Increasing available dopamine may improve slowness, stiffness or tremor, although every symptom does not respond equally.
Movement depends on coordinated signals between several brain regions. When dopamine signalling is reduced, everyday actions can take longer and feel less automatic.
A missed dose is normally followed by the next scheduled dose rather than an extra tablet. A different instruction may apply in an individual treatment plan, so the prescriber’s direction takes priority.
Rasagiline requires extra caution in hepatic impairment because liver function affects medicine exposure. Mild, moderate and severe liver impairment do not carry identical prescribing considerations.
Abnormal liver tests, previous hepatitis, cirrhosis or unexplained jaundice should be disclosed before the regimen is confirmed. The EMA product information describes restrictions and precautions for hepatic impairment [1].
CYP1A2 inhibitors can increase rasagiline exposure. Ciprofloxacin is the practical example most often missed because it may be prescribed by a clinician who does not manage the person’s Parkinson’s treatment.
The prescriber or pharmacist must assess the combination before the antibiotic is started. Do not alter or stop an antibiotic independently.
Different Parkinson’s treatments act at different points in dopamine signalling. The choice depends on age, cognition, falls, hallucinations, daytime sleepiness, symptom pattern and existing medicines.
| Treatment approach | Main action and practical limitation |
|---|---|
| Rasagiline | Inhibits MAO-B and may support dopamine signalling; interaction screening and sleepiness monitoring remain necessary. |
| Levodopa | Replaces dopamine precursor activity and often provides strong motor relief; wearing-off and dyskinesia may develop over time. |
| Dopamine agonists | Stimulate dopamine receptors directly; sleepiness, hallucinations, swelling and impulse-control problems can affect suitability. |
| Safinamide | Provides MAO-B inhibition with additional glutamate-related activity; interaction and liver considerations require review. |
| Selegiline | MAO-B inhibition with a different metabolic profile; insomnia and interaction concerns can influence its use. |
Levodopa is converted into dopamine in the brain, while rasagiline reduces dopamine breakdown. They may be used together when levodopa-related off-time becomes a treatment concern.
The combination can also increase the chance of dyskinesia in some people. Changes in involuntary movement should be reported rather than managed by skipping tablets.
Dopamine agonists stimulate dopamine receptors directly. Their adverse-effect profile can include sleep attacks, hallucinations, ankle swelling and impulse-control disorders, so these effects may influence treatment selection.
Rasagiline has a different mechanism, but it can still contribute to somnolence and interaction risk. Neither approach is universally preferable.
Safinamide and selegiline also affect dopamine-related pathways, yet their pharmacology and interaction profiles differ. The UK prescribing information, individual medicines and the person’s existing regimen determine whether any switch is appropriate.
A comparison by mechanism does not provide a safe switching schedule. Any change needs a planned dose transition and monitoring.
Common mistakes include:
Another practical point is that a person may not recognise a sleep episode as a medicine effect. A family member may notice brief nodding-off during conversation before the patient does.
Azilect is not suitable for everyone. NOT for you if: you have a contraindication, an unresolved interaction risk, or hepatic impairment that makes rasagiline unsuitable. The following situations require exclusion, careful review or a prescriber-led decision before treatment:
Tell the prescriber about Azilect before an antibiotic is selected. Include herbal products, non-prescription pain medicines, cold remedies and recreational substances when the medication list is reviewed.
Azilect can cause unwanted effects, and some symptoms may also arise from Parkinson’s disease or another medicine. Report persistent or troublesome symptoms rather than stopping treatment abruptly.
Reported effects can include flu syndrome, joint pain or swelling and indigestion. Nausea, headache or general discomfort may also occur in clinical practice.
Small practical changes can help with mild indigestion, but persistent vomiting, dehydration or severe abdominal symptoms need medical review. New joint swelling should be reported when it persists or limits walking.
Azilect may be associated with high blood pressure or hypertension, while Parkinson’s disease and Parkinson’s medicines can also contribute to hypotension or orthostatic hypotension. Orthostatic hypotension means a fall in blood pressure after standing, which can cause dizziness or fainting.
Move from lying to sitting and then standing gradually. Repeated falls, fainting, chest pain or severe headache require prompt medical assessment.
Somnolence means excessive sleepiness. Some people taking dopaminergic treatment have fallen asleep during ordinary activities, including while sitting, eating or travelling.
Do not drive or operate machinery if unusually sleepy. Sudden sleep episodes require prompt contact with the prescriber because the treatment plan and work or driving safety may need review.
Serotonin syndrome is an uncommon but serious reaction involving excessive serotonin activity. Warning symptoms include agitation, confusion, fever, sweating, tremor, diarrhoea, fast heartbeat and marked muscle rigidity.
Seek urgent medical assessment for severe headache, chest pain, fainting, confusion, high fever, pronounced rigidity or breathing difficulty. Dyskinesia may appear as uncontrolled twisting or jerking and can require supervised adjustment of Parkinson’s treatment.
In clinical practice, doctors often focus on the daily pattern of movement rather than a single good or bad morning. A symptom diary showing medication times, walking ability, stiffness, tremor, sleepiness and involuntary movement can reveal wearing-off that is difficult to describe from memory.
One useful record is a simple timeline: dose time, first improvement, return of stiffness, falls, sleepiness and involuntary movement. This does not replace examination, but it gives the clinician clearer information for treatment planning.
Azilect is prescribed as a once-daily treatment because rasagiline produces sustained MAO-B inhibition beyond the time its concentration is highest in the blood. The clinical benefit is assessed across daily movement patterns rather than by timing one tablet against one immediate effect. EMA product information from 2024 describes once-daily administration and the need to assess the regimen within the wider Parkinson’s treatment plan.
A lack of noticeable improvement should lead to a structured treatment review, not an extra tablet. The clinician may assess diagnosis, disease stage, timing, levodopa response, sleep, falls and other causes of poor mobility. FDA prescribing information from 2021 supports individual assessment because response varies between patients and treatment settings.
Do not split, crush or chew the tablet unless the prescriber or dispensing pharmacist has given a specific instruction for the supplied formulation. Altering a tablet can affect how it is swallowed and may make accurate dosing more difficult. MHRA product information from 2025 should guide the administration details for the UK presentation.
Yes. Somnolence and sudden sleep episodes can impair driving, concentration and machinery work. Do not drive or operate machinery while unusually sleepy, and report sudden sleep episodes promptly. MHRA safety information current to 2025 places practical emphasis on recognising sleep-related impairment during dopaminergic treatment.
Take the next scheduled dose rather than doubling it, unless the prescriber has issued different instructions. An extra dose can increase adverse effects without reliably restoring symptom control. EMA product information from 2024 supports keeping dosing regular and avoiding unsupervised changes. Contact the prescriber if missed doses happen repeatedly or symptoms change.
Azilect contains rasagiline, which inhibits MAO-B and reduces dopamine breakdown. Safinamide also affects MAO-B but has additional pharmacological activity, while selegiline has a different metabolic profile and may produce different tolerability concerns. NICE Parkinson’s guidance from 2017 places these options within an individualised treatment strategy rather than naming one universally preferred medicine.
Some combinations require strict prescribing oversight because serotonergic medicines may contribute to serotonin syndrome risk. Warning symptoms include agitation, fever, sweating, tremor, diarrhoea and muscle rigidity. MHRA product information from 2025 should be checked for the specific medicine, dose and any required treatment interval before combination treatment is started.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
Based on 4 reviews
Movement felt less stiff in the mornings, and I noticed fewer short periods when walking became difficult. The first weeks brought mild indigestion, which settled without stopping the tablets.
Bath Several months 28 Oct 2026The benefit was gradual rather than dramatic. I had better control before lunch, but later developed more involuntary movement, so my Parkinson’s appointment became focused on timing and adjustment.
Coventry Several months 30 Sept 2026I missed one dose and took the next one at the usual time instead of doubling it. I did not notice a sudden change, although the first month included light-headedness when standing.
Aberdeen One month 16 Oct 2026The medicine seemed to reduce some off-time, but daytime sleepiness became a real problem during desk work. I stopped driving until the prescriber reviewed the treatment.
Sunderland Several months 8 Oct 2026
